Clinical trial of treatment of laryngeal cancer by recombinant adenovirus p53 combined with chemotherapy.
- Author:
Xiaohui DOU
1
;
Xiaoming ZHAO
;
Yanqun WANG
;
Liang ZENG
;
Zhiwei WANG
Author Information
1. Department of Otolaryngology, People's Hospital of Zhuhai, Zhuhai, 519000, China. douxiaohui66@hotmail.com
- Publication Type:Journal Article
- MeSH:
Adenoviridae;
genetics;
Animals;
Drug Evaluation, Preclinical;
Female;
Genes, p53;
Genetic Therapy;
Genetic Vectors;
Laryngeal Neoplasms;
therapy;
Mice;
Mice, Inbred C3H;
Neoplasms, Experimental
- From:
Journal of Clinical Otorhinolaryngology Head and Neck Surgery
2007;21(18):848-850
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To evaluate the effectiveness of recombinant adenovirus p53 injection (rAd2p53) combined with cisplatin plus 5-fluorouracil regimen in treating laryngeal carcinoma.
METHOD:Tumour animal models were established in the back of mice with Hep-2 cell line. Recombinant adenovirus p53 injection (rAd2p53) were transduced to tumor-bearing mouse by direct intratumoral injection combine with cisplatin plus 5-fluorouracil ivgtt. The control group 1 was given recombinant adenovirus p53 injection (rAd2p53) simplex. The control group 2 was administered with cisplatin plus 5-fluorouracil ivgtt simplex. Then compare the diameters of pro-treatment with that of post-treatment and test group with controls.
RESULT:Tumor growth was significantly inhibited following combined rAd2p53 gene therapy with cisplatin plus 5-fluorouracil chemotherapy compared to single rAd2p53 gene therapy and cisplatin plus 5-fluorouracil chemotherapy controls.
CONCLUSION:Local injection of rAd2p53 combined with cisplatin plus 5-fluorouracil chemotherapy is a promising treatment to laryngeal cancer.
